Sensome has secured €4.6m funding to be used for the commercialization of its Clotild smart stroke guidewire.
The company has secured funding under the financing round led by Kurma Partners. It headed the existing venture capital syndicate, including Paris-Saclay Seed Fund and Idinvest.
Other historical investors and venture capital firm BNP Paribas Développement were also participated in the financing round.
Sensome CEO and co-founder Franz Bozsak said: “This financing round will enable us to bring Clotild through clinical testing and to the European market, and to explore the next applications of our technology.”
Sensome’ advanced sensing technology aggregates impedance-based micro-sensors with machine learning algorithms to immediately identify biological tissues with an unequaled predictive reliability.
The sensors are very thin, which makes them to be seamlessly incorporated with any medical device.
Clotild is claimed to be the first product to incorporate Sensome’s technology. It is a connected guidewire designed to treat ischemic stroke, the major cause of disability.
Millions of brain cells will die every minute, when a brain blood vessel is blocked by a clot. Based on the content of the clot, the emergency intervention to reopen the clogged artery will take hours of time.
Clotild has capacity to immediately open the clot content to help physicians select the optimal tools for each patient and reestablish blood flow.
Sensome board director and Kurma Partners representative Philippe Peltier said: “We have been very impressed by Sensome’s progress over the past year.
“We share Sensome’s vision of connected medical devices to benefit an extended number of patients and are excited to be part of this upcoming revolution.”
Sensome is engaged in the development of breakthrough remote monitoring technology, which can turn invasive vascular medical devices into connected healthcare devices.
The firm’s patent-pending technology can overcome the limitations of vascular imaging techniques used in both interventions and patient follow-up by providing instantaneous and non-invasive identification of the tissue composition in contact with a medical device follow-up.